Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GULLIVER-2 - A Single (Open-label) and Repeat Dose (Randomised, Placebo-controlled) Trial to Assess the Safety, Tolerability and Pharmacokinetics of GB1211 in Participants With Hepatic Impairment (Child Pugh B & C)

NCT05009680 is registered in ClinicalTrials.gov with Galecto Biotech AB as lead sponsor.

NCT NCT05009680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05009680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GULLIVER-2 - A Single (Open-label) and Repeat Dose (Randomised, Placebo-controlled) Trial to Assess the Safety, Tolerability and Pharmacokinetics of GB1211 in Participants With Hepatic Impairment (Child Pugh B & C)
Lead sponsor
Galecto Biotech AB
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 9, 2021
Completion date
July 4, 2023
Enrollment
54 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment